As many as 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine.

Leading oncology centers in the United States engaged to conduct the Phase 2 Antiviral Trial and further advance the development of PUL-042 HOUSTON, TX, UNITED STATES, July 8, 2025 /EINPresswire.com/ ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

Until relatively recently there had been episodes when children had been admitted into hospitals with symptoms that were similar to those expected for human respiratory syncytial virus (HRSV), but ...

Credit "Human Respiratory Syncytial Virus (RSV)" by NIAID Image Source Link: https://openverse.org/image/05511ba8-32c8-44ec-b14f-61faf6e57bd6?q=Respiratory+syncytial ...

Chicago, June 09, 2025 (GLOBE NEWSWIRE) -- The global respiratory syncytial virus treatment market valued at USD 2,387.2 million in 2024 and is projected to reach USD 8,332.5 million by 2033 ...

Test positivity for common cold coronaviruses significantly declined following widespread SARS-CoV-2 infection and COVID-19 ...